About Pfizer Inc.
https://www.pfizer.comPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
CEO
Albert Bourla
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-17 | Forward | 527:500 |
| 1999-07-01 | Forward | 3:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.22%
Shares:178.49M
IHVV.AX
Weight:0.24%
Shares:72.83M
XUS.TO
Weight:0.24%
Shares:72.83M
Summary
Showing Top 3 of 897
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Guggenheim
Buy
Morgan Stanley
Equal Weight
B of A Securities
Neutral
Citigroup
Neutral
UBS
Neutral
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:5.61B
Value:$143.58B
VANGUARD GROUP INC
Shares:534.32M
Value:$13.67B
BLACKROCK, INC.
Shares:497.43M
Value:$12.72B
Summary
Showing Top 3 of 3,952
About Pfizer Inc.
https://www.pfizer.comPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $16.65B ▲ | $8.93B ▲ | $3.54B ▲ | 21.26% ▲ | $0.62 ▲ | $5.65B ▲ |
| Q2-2025 | $14.65B ▲ | $5.84B ▲ | $2.91B ▼ | 19.86% ▼ | $0.51 ▼ | $5.32B ▲ |
| Q1-2025 | $13.71B ▼ | $5.2B ▼ | $2.97B ▲ | 21.63% ▲ | $0.52 ▲ | $5.06B ▼ |
| Q4-2024 | $17.76B ▲ | $7.24B ▲ | $403M ▼ | 2.27% ▼ | $0.07 ▼ | $5.14B ▼ |
| Q3-2024 | $17.7B | $5.8B | $4.47B | 25.27% | $0.79 | $7.25B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $14.98B ▲ | $208.73B ▲ | $115.64B ▼ | $92.8B ▲ |
| Q2-2025 | $13.25B ▼ | $206.09B ▼ | $117.08B ▼ | $88.69B ▼ |
| Q1-2025 | $17.32B ▼ | $208.03B ▼ | $117.39B ▼ | $90.34B ▲ |
| Q4-2024 | $20.48B ▲ | $213.4B ▼ | $124.9B ▼ | $88.2B ▼ |
| Q3-2024 | $9.95B | $219.48B | $126.92B | $92.29B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.55B ▲ | $4.6B ▲ | $-2.43B ▼ | $-2.48B ▲ | $-300M ▼ | $4B ▲ |
| Q2-2025 | $2.93B ▼ | $-582M ▼ | $3.95B ▲ | $-3.2B ▲ | $213M ▼ | $-1.2B ▼ |
| Q1-2025 | $2.97B ▲ | $2.33B ▼ | $3.27B ▲ | $-5.23B ▼ | $374M ▲ | $1.77B ▼ |
| Q4-2024 | $411M ▼ | $6.72B ▲ | $-1.62B ▲ | $-5.11B ▼ | $-45M ▼ | $5.8B ▼ |
| Q3-2024 | $4.48B | $6.71B | $-2.06B | $-4.64B | $40M | $6.06B |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Biopharma Segment | $17.39Bn ▲ | $17.41Bn ▲ | $14.30Bn ▼ | $16.31Bn ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Developed Rest Of World | $6.28Bn ▲ | $3.41Bn ▼ | $3.39Bn ▼ | $3.70Bn ▲ |
 Emerging Markets | $2.26Bn ▲ | $2.23Bn ▼ | $2.37Bn ▲ | $2.27Bn ▼ |
 UNITED STATES | $9.22Bn ▲ | $12.06Bn ▲ | $8.89Bn ▼ | $10.69Bn ▲ |
CEO
Albert Bourla
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-17 | Forward | 527:500 |
| 1999-07-01 | Forward | 3:1 |
ETFs Holding This Stock
VTS.AX
Weight:0.22%
Shares:178.49M
IHVV.AX
Weight:0.24%
Shares:72.83M
XUS.TO
Weight:0.24%
Shares:72.83M
Summary
Showing Top 3 of 897
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Guggenheim
Buy
Morgan Stanley
Equal Weight
B of A Securities
Neutral
Citigroup
Neutral
UBS
Neutral
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:5.61B
Value:$143.58B
VANGUARD GROUP INC
Shares:534.32M
Value:$13.67B
BLACKROCK, INC.
Shares:497.43M
Value:$12.72B
Summary
Showing Top 3 of 3,952